Global study tracks Real-World impact of new heart drug

NCT ID NCT07358078

First seen Jan 26, 2026 · Last updated May 06, 2026 · Updated 15 times

Summary

This study will follow about 2000 adults with a rare heart condition called ATTR-CM, where abnormal proteins build up in the heart. Participants are starting treatment with the drug vutrisiran or another approved therapy. Researchers will track symptoms, quality of life, and healthcare needs over time to see how well the treatments work in everyday medical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Clinical Trial Site

    RECRUITING

    Naples, Florida, 34102, United States

  • Clinical Trial Site

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Clinical Trial Site

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

  • Clinical Trial Site

    RECRUITING

    Memphis, Tennessee, 38120, United States

Conditions

Explore the condition pages connected to this study.